2 results
Approved WMORecruiting
The primary objective of this trial in CIAS is to assess the efficacy in improving cognitive impairment using MCCB in patients with schizophrenia treated for 26 weeks with Iclepertin 10mg as compared with placebo.
Approved WMORecruiting
Phase 1• To establish the RP2D regimen by evaluation of the safety and tolerability of intravenous (IV) administration of Lutetium (177Lu) rhPSMA-10.1 injection in subjects with mCRPC.Phase 2• To evaluate the efficacy of Lutetium (177Lu) rhPSMA-10.1…